摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-hydroxy-pyrrolidin-1-yl-acetonitrile | 857637-01-5

中文名称
——
中文别名
——
英文名称
3-hydroxy-pyrrolidin-1-yl-acetonitrile
英文别名
2-(3-Hydroxypyrrolidin-1-yl)acetonitrile
3-hydroxy-pyrrolidin-1-yl-acetonitrile化学式
CAS
857637-01-5
化学式
C6H10N2O
mdl
——
分子量
126.158
InChiKey
ZJKMVVGNSMLLAV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.4
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    47.3
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    3-羟基吡咯烷溴乙腈四氢呋喃 为溶剂, 以The title-compound was yielded as a straw-coloured oil (15.39 g, 71%) after flash chromatography的产率得到3-hydroxy-pyrrolidin-1-yl-acetonitrile
    参考文献:
    名称:
    Antharquinone Compounds as Anti Cancer Compounds
    摘要:
    通式(I)或其盐(式I)的蒽醌化合物,其中R1至R4均选自H、C1-4烷基、X1、-NHR0N(Rs)2的群,其中R°是C1l12烷二基,每个R5是H或可选取代的C14烷基,以及式(II)的一组,其中至少有一个R6、R7和R8选自X2和X2取代的C1-4烷基,其余为H或C14烷基;R9选自H、C14烷基、X2和X2取代的C1-4烷基;m为0或1;n为1或2;X1为卤素原子、羟基、C1.6烷氧基、芳基氧基或酰氧基;X2为卤素原子、羟基、C16烷氧基、芳基氧基或酰氧基;前提是至少有一个R1至R4是式(II)的一组。N-氧化物是有用的前药,在低氧肿瘤中选择性地生物还原为相应的环状胺衍生物。胺化合物具有细胞毒性,并可用作具有拓扑异构酶II抑制活性的烷基化剂,用于癌症治疗。
    公开号:
    US20080027107A1
点击查看最新优质反应信息

文献信息

  • SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS
    申请人:Dr. Reddy's Laboratories Ltd.
    公开号:US20150005280A1
    公开(公告)日:2015-01-01
    The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.
    本申请涉及一系列取代吡唑并[1,5-a]吡啶化合物,其作为肌浆蛋白受体激酶(Trk)家族蛋白激酶抑制剂的用途,制备方法以及包含这些化合物的药物组合物。
  • [EN] ANTHARQUINONE COMPOUNDS AS ANTI CANCER COMPOUNDS<br/>[FR] UTILISATION DE COMPOSES D'ANTHRAQUINONE EN TANT QUE COMPOSES ANTICANCEREUX
    申请人:UNIV LONDON PHARMACY
    公开号:WO2005061453A1
    公开(公告)日:2005-07-07
    Anthraquinone compounds of the general formula (I) or a salt thereof (Formula I) in which R1 to R4 are each selected from the group consisting of H, C1-4 alkyl, X1, -NHR0N (R5)2 in which R0 is a C1-12 alkanediyl and each R5 is H or optionally substituted C1-4 alkyl, and a group of formula (II) in which at least one of R6,R7 and R8 is selected from X2 , and X2 substituted C1-4 alkyl and any others are H or C1-4 alkyl; R9 is selected from H, C1-4 alkyl, X2 and X2 substituted C1-4 alkyl; m is 0 or 1; n is 1 or 2; X1 is a halogen atom, a hydroxyl group, a C1-6 alkoxyl group, an aryloxy group or an acyloxy group; and X2 is a halogen atom, a hydroxyl group, a C1-6 alkoxyl group, an aryloxy group or an acyloxy group; provided that at least one of R1 to R4 is a group of formula (II). The N-oxides are useful prodrugs which are selectively bioreduced in hypoxic tumours to the corresponding cyclic amine derivatives. The amine compounds are cytotoxic and may be used as alkylating agents having topoisomerase II inhibiting activities in cancer therapy.
    通式(I)的蒽醌化合物或其盐(公式I),其中R1至R4分别选自H、C1-4烷基、X1、-NHR0N(R5)2,其中R0为C1-12烷二基,每个R5为H或可选择性取代的C1-4烷基,以及公式(II)中的一组,其中R6、R7和R8中至少有一个选自X2,和X2取代的C1-4烷基,其他为H或C1-4烷基;R9选自H、C1-4烷基、X2和X2取代的C1-4烷基;m为0或1;n为1或2;X1为卤素原子、羟基、C1-6烷氧基、芳基氧基或酰氧基;X2为卤素原子、羟基、C1-6烷氧基、芳基氧基或酰氧基;前提是R1至R4中至少有一个是公式(II)的一组。N-氧化物是有用的前药,可选择性地在低氧肿瘤中生物还原为相应的环胺衍生物。胺化合物具有细胞毒性,可用作在癌症治疗中具有拓扑异构酶II抑制活性的烷基化剂。
  • [EN] N-ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY<br/>[FR] DERIVES DU N-ARYL-N'-ARYLCYCLOALKYL-UREE, ANTAGONISTES DE L'HORMONE MCH, TRAITANT L'OBESITE
    申请人:SCHERING CORP
    公开号:WO2003047568A1
    公开(公告)日:2003-06-12
    The present invention discloses compounds of the formula I which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    本发明揭示了式I的化合物,它们是黑色素浓聚激素(MCH)的新型拮抗剂,以及制备这些化合物的方法。在另一实施例中,本发明揭示了包含这些MCH拮抗剂的药物组合物,以及使用它们治疗肥胖症、代谢紊乱、食欲紊乱(如暴食症)和糖尿病的方法。
  • MCH antagonists for the treatment of obesity
    申请人:Schering Corporation
    公开号:US20040122017A1
    公开(公告)日:2004-06-24
    The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    本发明揭示了一些化合物,这些化合物是黑色素浓聚激素(MCH)的新型拮抗剂,并揭示了制备这些化合物的方法。在另一种实施方式中,本发明揭示了包含这些MCH拮抗剂的药物组合物,以及使用它们治疗肥胖、代谢紊乱、进食障碍如过度进食和糖尿病的方法。
  • Antharquinone Compounds as Anti Cancer Compounds
    申请人:Patterson Laurence Hylton
    公开号:US20080027107A1
    公开(公告)日:2008-01-31
    Anthraquinone compounds of the general formula (I) or a salt thereof (Formula I) in which R 1 to R 4 are each selected from the group consisting of H, C 1-4 alkyl, X 1 , —NHR 0 N (Rs)2 in which R° is a C 1 l 12 alkanediyl and each R 5 is H or optionally substituted C 14 alkyl, and a group of formula (11) in which at least one of R 6 ,R 7 and R 8 is selected from X 2 , and X 2 substituted C 1-4 alkyl and any others are H or C 14 alkyl; R 9 is selected from H, C 1 4 alkyl, X 2 and X 2 substituted C 1-4 alkyl; m is 0 or 1; n is 1 or 2; X 1 is a halogen atom, a hydroxyl group, a C 1 . 6 alkoxyl group, an aryloxy group or an acyloxy group; and X 2 is a halogen atom, a hydroxyl group, a C 1 6 alkoxyl group, an aryloxy group or an acyloxy group; provided that at least one of R 1 to R 4 is a group of formula (II). The N-oxides are useful prodrugs which are selectively bioreduced in hypoxic tumours to the corresponding cyclic amine derivatives. The amine compounds are cytotoxic and may be used as alkylating agents having topoisomerase II inhibiting activities in cancer therapy.
    通式(I)或其盐(式I)的蒽醌化合物,其中R1至R4均选自H、C1-4烷基、X1、-NHR0N(Rs)2的群,其中R°是C1l12烷二基,每个R5是H或可选取代的C14烷基,以及式(II)的一组,其中至少有一个R6、R7和R8选自X2和X2取代的C1-4烷基,其余为H或C14烷基;R9选自H、C14烷基、X2和X2取代的C1-4烷基;m为0或1;n为1或2;X1为卤素原子、羟基、C1.6烷氧基、芳基氧基或酰氧基;X2为卤素原子、羟基、C16烷氧基、芳基氧基或酰氧基;前提是至少有一个R1至R4是式(II)的一组。N-氧化物是有用的前药,在低氧肿瘤中选择性地生物还原为相应的环状胺衍生物。胺化合物具有细胞毒性,并可用作具有拓扑异构酶II抑制活性的烷基化剂,用于癌症治疗。
查看更多

同类化合物

(2R,2''R)-(-)-2,2''-联吡咯烷 麦角甾-7,22-二烯-3-基亚油酸酯 马来酰亚胺霉素 马来酰亚胺基甲基-3-马来酰亚胺基丙酸酯 马来酰亚胺丙酰基-dPEG4-NHS 马来酰亚胺-酰胺-PEG6-琥珀酰亚胺酯 马来酰亚胺-酰胺-PEG24-丙酸 马来酰亚胺-酰胺-PEG12-丙酸 马来酰亚胺-四聚乙二醇-羧酸 马来酰亚胺-四聚乙二醇-丙酸叔丁酯 马来酰亚胺-六聚乙二醇-丙酸叔丁酯 马来酰亚胺-二聚乙二醇-丙酸叔丁酯 马来酰亚胺-三(乙烯乙二醇)-丙酸 马来酰亚胺-一聚乙二醇-羧酸 马来酰亚胺-一聚乙二醇-丙烯酸琥珀酰亚胺酯 马来酰亚胺-PEG3-羟基 马来酰亚胺-PEG2-胺三氟醋酸盐 马来酰亚胺-PEG2-琥珀酰亚胺酯 马来酰亚胺 频哪醇硼酸酯 顺式4-甲基吡咯烷酮-3-醇盐酸盐 顺式3,4-二氨基吡咯烷-1-羧酸叔丁酯 顺式-二甲基 1-苄基吡咯烷-3,4-二羧酸 顺式-N-[2-(2,6-二甲基-1-哌啶基)乙基]-2-氧代-4-苯基-1-吡咯烷乙酰胺 顺式-N-Boc-吡咯烷-3,4-二羧酸 顺式-5-苄基-2-叔丁氧羰基六氢吡咯并[3,4-c]吡咯 顺式-4-氧代-六氢-吡咯并[3,4-C]吡咯-2-甲酸叔丁酯 顺式-3-氟-4-羟基吡咯烷-1-羧酸叔丁酯 顺式-3-氟-4-甲基吡咯烷盐酸盐 顺式-2-甲基六氢吡咯并[3,4-c]吡咯 顺式-2,5-二甲基吡咯烷 顺式-1-苄基-3,4-吡咯烷二甲酸二乙酯 顺式-(9CI)-3,4-二乙烯-1-(三氟乙酰基)-吡咯烷 顺-八氢环戊[c]吡咯-5-酮盐酸盐 非星匹宁 阿维巴坦中间体1 阿曲生坦中间体 阿曲生坦 间甲氧基苯乙腈 铂(2+)羟基乙酸酯-吡咯烷-3-胺(1:1:1) 钾2-氧代吡咯烷-1-磺酸酯 钠1-[(9E)-9-十八碳烯酰基氧基]-2,5-二氧代-3-吡咯烷磺酸酯 金刚烷-1-基(吡咯烷-1-基)甲酮 酸-1-吡咯烷-1,4-氨基-2-甲基-1,1,1-二甲基乙基酯,(2S,4R)- 酚丙氢吡咯 试剂3-Mercaptopropanyl-N-hydroxysuccinimideester 西他利酮 血红素酸 螺虫乙酯残留代谢物Mono-Hydroxy 萘吡坦